171 related articles for article (PubMed ID: 38392051)
21. Pharmaceutical advances in the treatment of gastric adenocarcinoma.
Rogers JE; Sewastjanow D Silva M; Waters RE; Ajani JA
Expert Opin Pharmacother; 2022 Apr; 23(5):611-621. PubMed ID: 35098851
[TBL] [Abstract][Full Text] [Related]
22. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
Front Immunol; 2022; 13():885424. PubMed ID: 35837391
[TBL] [Abstract][Full Text] [Related]
23. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.
Sahin U; Schuler M; Richly H; Bauer S; Krilova A; Dechow T; Jerling M; Utsch M; Rohde C; Dhaene K; Huber C; Türeci Ö
Eur J Cancer; 2018 Sep; 100():17-26. PubMed ID: 29936063
[TBL] [Abstract][Full Text] [Related]
24. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
Dai J; Zheng H; Jin J; Cheng Y; Xu H
Cancer Cytopathol; 2023 Jun; 131(6):365-372. PubMed ID: 36793190
[TBL] [Abstract][Full Text] [Related]
25. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.
Wang X; Zhang CS; Dong XY; Hu Y; Duan BJ; Bai J; Wu YY; Fan L; Liao XH; Kang Y; Zhang P; Li MY; Xu J; Mao ZJ; Liu HT; Zhang XL; Tian LF; Li EX
World J Gastrointest Oncol; 2022 Jul; 14(7):1252-1264. PubMed ID: 36051096
[TBL] [Abstract][Full Text] [Related]
26. Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies.
Grizzi G; Venetis K; Denaro N; Bonomi M; Celotti A; Pagkali A; Hahne JC; Tomasello G; Petrelli F; Fusco N; Ghidini M
J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109309
[TBL] [Abstract][Full Text] [Related]
27. Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma.
Lordick F; Al-Batran SE; Ganguli A; Morlock R; Sahin U; Türeci Ö
Gastric Cancer; 2021 May; 24(3):721-730. PubMed ID: 33755863
[TBL] [Abstract][Full Text] [Related]
28. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
Cao W; Xing H; Li Y; Tian W; Song Y; Jiang Z; Yu J
Biomark Res; 2022 May; 10(1):38. PubMed ID: 35642043
[TBL] [Abstract][Full Text] [Related]
29. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
[TBL] [Abstract][Full Text] [Related]
30. Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer.
Zhang J; Dong R; Shen L
Chin J Cancer Res; 2020 Apr; 32(2):263-270. PubMed ID: 32410803
[TBL] [Abstract][Full Text] [Related]
31. Claudin18.2 in Advanced Gastric Cancer.
Inamoto R; Takahashi N; Yamada Y
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136288
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma.
Huang Y; You M; Wu Q; Chen R
Front Pharmacol; 2023; 14():1238009. PubMed ID: 37719841
[No Abstract] [Full Text] [Related]
33. The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.
Simon AG; Lyu SI; Laible M; Wöll S; Türeci Ö; Şahin U; Alakus H; Fahrig L; Zander T; Buettner R; Bruns CJ; Schroeder W; Gebauer F; Quaas A
J Transl Med; 2023 Aug; 21(1):552. PubMed ID: 37592303
[TBL] [Abstract][Full Text] [Related]
34. Advances in targeted therapy for gastric cancer based on tumor driver genes.
Wu S; Xu P; Zhang F
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 53(1):73-83. PubMed ID: 38413217
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma.
Kayikcioglu E; Yüceer RO; Cetin B; Yüceer K; Karahan N
World J Gastrointest Oncol; 2023 Feb; 15(2):343-351. PubMed ID: 36908327
[TBL] [Abstract][Full Text] [Related]
36. Safety and Pharmacokinetic Assessment of the FIC CLDN18.2/4-1BB Bispecific Antibody in Rhesus Monkeys.
Wang J; Dong T; Gong X; Li D; Sun J; Luo Y; Wu H
Int J Toxicol; 2024; 43(3):291-300. PubMed ID: 38115178
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
38. Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets.
Elimova E; Song S; Shimodaira Y; Lin Q; Ajani JA
Ann Surg Oncol; 2016 Nov; 23(12):3786-3791. PubMed ID: 27503493
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis.
Liu S; Wong HY; Xie L; Kim Y; Shu D; Zheng B; Liu N; Xing C; Chen X; Dong Q
Sci Rep; 2022 Dec; 12(1):22024. PubMed ID: 36539429
[TBL] [Abstract][Full Text] [Related]
40. [
Zeng Z; Li L; Tao J; Liu J; Li H; Qian X; Yang Z; Zhu H
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1221-1232. PubMed ID: 38062170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]